Physician profile
Alan M Bulbin
NPI 1053360628
$125,893.91
in general payments reported to CMS, 2019-2025
24 companies · $56K in 2025
The $56K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,301 · 2021: $2,527 · 2022: $17K · 2023: $8,380 · 2024: $23K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $9,640 · Food and Beverage: $6,664 · Travel and Lodging: $4,531 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,523.71 |
| Consulting Fee | $9,639.50 |
| Food and Beverage | $6,663.95 |
| Travel and Lodging | $4,531.20 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $35,170.43 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Cumberland Pharmaceuticals, INC. | $22,843.17 | 2019-2025 | Vibativ, Caldolor |
| Melinta Therapeutics, LLC | $22,268.09 | 2019-2025 | Kimyrsa, Vabomere, Rezzayo |
| Pfizer INC. | $16,295.37 | 2019-2025 | |
| Allergan, INC. | $12,752.35 | 2019-2020 | |
| Abbvie INC. | $11,196.99 | 2022-2025 | Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $2,592.80 | 2019-2025 | Pifeltro, Dificid, Bridion |
| Gilead Sciences, INC. | $1,026.71 | 2019-2025 | Biktarvy, Veklury |
| Shionogi INC | $300.28 | 2020-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $268.07 | 2020-2022 | |
| Astellas Pharma US INC | $242.41 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $201.96 | 2024-2025 | Vowst, Zenpep |
| Insmed, INC. | $178.95 | 2021-2025 | Arikayce |
| Sanofi Pasteur INC. | $155.60 | 2020-2025 | |
| Paratek Pharmaceuticals, INC. | $146.45 | 2023-2025 | Nuzyra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $60.91 | 2020-2023 | Symtuza |
| Napo Pharmaceuticals INC | $35.63 | 2019-2024 | Mytesi |
| Janssen Products, LP | $29.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Vyera Pharmaceuticals, LLC | $21.76 | 2019 | |
| Grifols USA, LLC | $19.55 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.46 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.40 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $19.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bulbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.